Literature DB >> 10096561

Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis.

A von Leoprechting1, P van der Bruggen, H L Pahl, A Aruffo, J C Simon.   

Abstract

Here, we report the functional expression of CD40 on human malignant melanomas (MMs). Comparison of tumor specimen from MM precursor lesions, primary tumors, and metastases revealed that CD40 surface expression is down-regulated during tumor progression. CD40 expression was confirmed in 7 human MM cell lines established from immunogenic primary tumors or metastases, whereas 11 cell lines established from advanced stages were CD40 negative. CD40 expression could be enhanced in CD40-positive MM by stimulation with IFN-gamma and tumor necrosis factor-alpha but not by interleukin (IL)-1beta or CD40 triggering. CD40 ligation on MM by CD40L-transfected murine L-cells or by a soluble CD40L fusion protein up-regulated their expression of intercellular adhesion molecule-1 and MHC class I and class II molecules and their secretion of IL-6, IL-8, tumor necrosis factor-a, and granulocyte macrophage colony-stimulating factor and also induced a rapid activation of the transcription factor nuclear factor kappaB. Furthermore, CD40 ligation of a HLA-A2+, MelanA/MART1+ MM cell line enhanced its susceptibility to specific lysis by a HLA-A2-restricted, MelanA/MART-1-specific CTL clone. Finally, CD40 ligation induced growth inhibition and apoptosis in MM. These results indicate that CD40-CD40L interactions may play an important role in augmenting antitumor immunity and inducing apoptosis in some CD40-positive immunogenic human MMs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096561

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy.

Authors:  Bernd Koppold; Georg Sauer; Hildegard Buening; Michael Hallek; Rolf Kreienberg; Helmut Deissler; Christian Kurzeder
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-23       Impact factor: 4.553

Review 2.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Authors:  Gregory L Beatty; Yan Li; Kristen B Long
Journal:  Expert Rev Anticancer Ther       Date:  2016-12-14       Impact factor: 4.512

3.  Differential induction of nuclear factor-kappaB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation.

Authors:  Jalal Ahmed-Choudhury; Clare L Russell; Satinder Randhawa; Lawrence S Young; David H Adams; Simon C Afford; Jalal Ahmed Choudhury
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

4.  Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.

Authors:  Rhea N Coler; Thomas Hudson; Sean Hughes; Po-Wei D Huang; Elyse A Beebe; Mark T Orr
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

Review 5.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

Review 6.  Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

Authors:  Jennifer D Moy; Jessica M Moskovitz; Robert L Ferris
Journal:  Eur J Cancer       Date:  2017-03-18       Impact factor: 9.162

7.  CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

Authors:  Geertje J D van Mierlo; Annemieke Th den Boer; Jan Paul Medema; Ellen I H van der Voort; Marieke F Fransen; Rienk Offringa; Cornelis J M Melief; Rene E M Toes
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

8.  CD4+T cells in CIKs (CD4+ CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation.

Authors:  Jinpu Yu; Weihong Zhang; Huawei Jiang; Hui Li; Shui Cao; Xinbao Ren
Journal:  Cancer Biother Radiopharm       Date:  2008-06       Impact factor: 3.099

9.  Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.

Authors:  Akemi Kosaka; Takayuki Ohkuri; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2014-05-31       Impact factor: 6.968

10.  Anti-CD40 agonist antibodies: preclinical and clinical experience.

Authors:  Magi Khalil; Robert H Vonderheide
Journal:  Update Cancer Ther       Date:  2007-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.